Melanotan I (Afamelanotide)


Alpha-MSH analog (linear heptadecapeptide)

A linear alpha-MSH analog approved as Scenesse for erythropoietic protoporphyria, characterized by sustained skin pigmentation.

Abstract

Melanotan I (Afamelanotide, Scenesse; (Nle4, D-Phe7)-alpha-MSH; CAS 75921-69-6; molecular formula C78H111N21O19; molecular weight 1646.85) is a linear heptadecapeptide analog of alpha-melanocyte stimulating hormone (alpha-MSH) developed at the University of Arizona by Mac Hadley’s group in the 1980s. The compound was approved by the FDA in 2019 (and earlier in Europe) for erythropoietic protoporphyria, a rare genetic photosensitivity disorder. Mechanism is non-selective melanocortin receptor agonism (MC1, MC3, MC4, MC5); the MC1 activity drives melanin synthesis in melanocytes producing tan-like skin pigmentation. The compound is sold as a research chemical/peptide for sunless tanning applications, though regulatory authorities have issued warnings against this use. Pharmacokinetics: subcutaneous administration; the implant formulation provides 30 to 60 days of activity per dose.

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.


Browse all monographs

Previous monograph
Next monograph